Tissue-Specific Effects of Tibolone: Preclinical Studies

Abstract

Get full access to this article

View all access options for this article.

References

1. Tax

Goorissen

Kicovic

. Clinical profile of Org OD14. Maturitas 1987: 3 Suppl 1: 3–13.

2. Markiewicz

Gurpide

In vitro evaluation of estrogenic, estrogenic antagonistic and progestagenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990; 35: 535–41.

3. Tang

Markiewicz

Kloosterboer

Gurpide

Human endometrial 3ß-hydroxysteroid dehydrogenose/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroid drug (Org OD14). J Steroid Biochem Mol Biol 1993; 45: 345–51.

4. Pasqualini

Chetrite

Activtiy, regulation and expression of sulfatase, sulfotransferase and 17ß-hydroxysteroid dehydrogenase in breast cancer. Hormone-dependent Cancer ( Pasqualini

Katzenellenbogen

eds). New York, Macel Dekker Inc., 1996, pp 25–80

5. Kloosterboer

Schoonen

WGEJ

Deckers

Klijn

JGM

. Effect of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994; 49: 311–318.

6. Gompel

Kandouz

Siromachkova

Lombet

Thevenin

Mimoun

Poitout

The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. (1997). Gynecol. Endocrinol. 1997; Suppl 1: 77–79.

7. Chetrite

Kloosterboer

Pasqualini

. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997; 17: 135–140.

8. Erel

Elter

Akman

Ersavasti

Altug

Seyisogluh Etungealp

Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998; 69: 870–875.